• By ICR Secretariat
  • Posted Monday, June 28, 2021

Trial failure dashes Biogen hopes for next Alzheimer's drug


  • An experimental Alzheimer's disease treatment developed by Biogen didn't slow patients' decline when compared to a placebo in a mid-stage study, leading the Massachusetts-based biotech to halt all work on the drug. Known as gosuranemab, the drug blocks a protein that accumulates in patients' brain called tau, which is different than the way Biogen's newly approved drug Aduhelm is designed to work.